This is the authors' abstract. We don't add key points for this paper.
The tRNA-derived small RNAs (tsRNAs), including tRNA-derived fragments (tRFs) and tRNA halves (tRHs), represent a highly evolutionarily conserved family produced via the selective enzymatic processing of full-length tRNAs. Functionally, tsRNAs play multifaceted regulatory roles, including translational repression through ribosome competition, stress granule assembly modulation, epigenetic reprogramming via chromatin remodeling complexes, and modulation of transgenerational inheritance pathways. While their potential as robust diagnostic and prognostic indicators for liver cancers, notably hepatocellular carcinoma, is growing, the detailed mechanistic contributions of tsRNAs to hepatocarcinogenesis remain an area requiring deeper investigation. This review provides a systematic aggregation of current findings on tsRNA generation, functional categorization, and their observed dysregulation within liver cancers, including primary and metastatic liver cancers. We also summarized the research pipeline utilizing animal models for investigating tsRNAs in hepatocellular carcinoma and outlined the sequential research strategies employed in preclinical models to translate tsRNA discoveries into clinical applications, establishing causal links between molecular alterations and disease pathology. In conclusion, tsRNAs are poised to become potential biomarkers for the early diagnosis and prognostic assessment, and novel nucleic acid-based targeted therapeutic strategies in liver cancer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: